Barreleye develops AI-based quantitative ultrasound diagnostic software that analyzes raw radio-frequency (RF) ultrasound signals rather than only B-mode images. Its deep-learning models extract tissue characterization information that previously required MRI, using standard ultrasound hardware. The company sells two product families, the Intelligent series (breast, hepatic, lung) and the Vision series (breast, cardiac, thyroid), and its breast ultrasound software has been designated an innovative medical device and cleared by Korea's MFDS. Founded in 2021 out of KAIST by Professor Hyeonmin Bae, it filed this Form D through its US entity, Barreleye US, Inc., in San Jose, California.